AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36091017 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors (RASi) at maximum tolerant dose for 3 months
Number of subjects: 370
Study 36091017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hub gene validation using real-time quantitative polymerase chain reaction (qRT-PCR)
Number of subjects: 370
Study 36091017 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis
Number of subjects: 370
Study 33509504 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 52
Study 33509504 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil
Number of subjects: 52
Study 33509504 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil
Number of subjects: 52
Study 33509504 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 52
Study 34168292 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein formula (Fresubin® Intensive; HPG)
Number of subjects: 18
Study 34168292 — intervention group
Group type: COMPARATOR
Intervention: Contemporary matched conventional therapy group (CTG)
Number of subjects: 18
Study 33413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly display condition
Number of subjects: 123
Study 33413307 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 123
Study 33413307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-FSA-J group
Number of subjects: 123
Study 33413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 123
Study 33070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cidofovir (first-line therapy)
Number of subjects: 6
Study 33070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical foscavir (first-line therapy)
Number of subjects: 6
Study 33070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscavir (first-line therapy)
Number of subjects: 6
Study 33070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cidofovir (second-line therapy)
Number of subjects: 6
Study 33070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical foscavir (second-line therapy)
Number of subjects: 6
Study 33070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscavir (second-line therapy)
Number of subjects: 6
Study 33070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 6
Study 36207701 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD system
Number of subjects: 154
Study 36207701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 36207701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 34610099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 100
Study 34610099 — intervention group
Group type: COMPARATOR
Intervention: Control (intermittent manual assistance)
Number of subjects: 100
Study 32927609 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean diet (AMedDiet)
Number of subjects: 62
Study 32927609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 62
Study 32927609 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal aerobic power (Vo2max)
Number of subjects: 62
Study 32927609 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula for predicting SBP
Number of subjects: 62
Study 36153555 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital format of the German schizophrenia guideline using MAGICapp
Number of subjects: 0
Study 36153555 — intervention group
Group type: COMPARATOR
Intervention: Classic print pdf version of the German schizophrenia guideline
Number of subjects: 0
Study 34541941 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-free dialysate
Number of subjects: 66
Study 34541941 — intervention group
Group type: COMPARATOR
Intervention: Glucose-containing dialysate (5.55 mmol/L)
Number of subjects: 66
Study 35104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical turmeric cream
Number of subjects: 30
Study 35104042 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study 32647961 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (180 subjects consisting of 90 males and 90 females) using combined CBCT and 3dMD photogrammetry system
Number of subjects: 240
Study 32647961 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (180 subjects)
Number of subjects: 240
Study 32647961 — intervention group
Group type: COMPARATOR
Intervention: Test group (60 subjects consisting of 30 males and 30 females)
Number of subjects: 240
Study 35227940 — intervention group
Group type: EXPERIMENTAL
Intervention: IR/ER-amantadine 193 mg
Number of subjects: 222
Study 35227940 — intervention group
Group type: EXPERIMENTAL
Intervention: IR/ER-amantadine 258 mg
Number of subjects: 222
Study 35227940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 33342523 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment schools with access to free breakfast, lunch, and supper on school days, and a food backpack on weekends and school breaks
Number of subjects: 2636
Study 33342523 — intervention group
Group type: COMPARATOR
Intervention: Control schools with a less robust set of benefits
Number of subjects: 2636
Study 35879482 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-enriched supplements (AES)
Number of subjects: 24
Study 35879482 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric/isonitrogenous control supplement
Number of subjects: 24
Study 33494640 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptospirosis
Number of subjects: 3699
Study 33494640 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptospirosis in males
Number of subjects: 3699
Study 33494640 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptospirosis in individuals aged 18-39
Number of subjects: 3699
Study 33494640 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptospirosis within first 2 years after diagnosis
Number of subjects: 3699
Study 35728386 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 68
Study 35728386 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 68
Study 32585923 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-driven redesign of instructional materials (instruction sheet, swing tags, online training videos)
Number of subjects: 0
Study 32585923 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-driven redesign of instructional materials
Number of subjects: 0
Study 35656683 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey solution (5 mL)
Number of subjects: 100
Study 35656683 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (5 mL)
Number of subjects: 100
Study 33628967 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention (n = 83)
Number of subjects: 166
Study 33628967 — intervention group
Group type: COMPARATOR
Intervention: Custom education (n = 83)
Number of subjects: 166
Study 36193978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT) with esomeprazole 40 mg and amoxicillin 1000 mg three times daily for 14 days
Number of subjects: 658
Study 36193978 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (TFEB) with esomeprazole 40 mg, bismuth potassium citrate 220 mg, furazolidone 100 mg twice daily, and tetracycline 500 mg three times daily for 14 days
Number of subjects: 658
Study 36193978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT)
Number of subjects: 658
Study 36193978 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (TFEB)
Number of subjects: 658
Study 32835882 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival scaling and root planing (SRP) + tg‐aPDT
Number of subjects: 40
Study 32835882 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling and root planing (SRP) alone
Number of subjects: 40
Study 35987013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg twice daily)
Number of subjects: 32
Study 35987013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33119363 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 2363
Study 33119363 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered care
Number of subjects: 2363
Study 32759251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dose of 30 mg/kg
Number of subjects: 30
Study 32759251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 30
Study 32759251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36278336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise therapy (SET) for 4 weeks
Number of subjects: 25
Study 36278336 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal activities of daily living)
Number of subjects: 25
Study 33960674 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline irrigation twice daily using a 250-ml squeeze bottle in addition to standard treatment
Number of subjects: 61
Study 33960674 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 61
Study 32787541 — intervention group
Group type: EXPERIMENTAL
Intervention: Active outreach strategies (e.g., tabling in busy areas, attending community events, utilising mixed media, collaborating with clinic staff)
Number of subjects: 314
Study 32787541 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies involving multiple staff in the field
Number of subjects: 314
Study 32787541 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and enrolment conducted over 122 trips from June 2015 to December 2018
Number of subjects: 314
Study 32787541 — intervention group
Group type: EXPERIMENTAL
Intervention: Community size
Number of subjects: 314
Study 33801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention for weight loss
Number of subjects: 576
Study 33801339 — intervention group
Group type: EXPERIMENTAL
Intervention: MC4R SNPs rs571312 and rs17782313
Number of subjects: 576
Study 33801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Other SNPs within FTO, TMEM18, SEC16B, BDNF
Number of subjects: 576
Study 33801339 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition score (GPS)
Number of subjects: 576
Study 32333010 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG+OPV vaccination at admission
Number of subjects: 268
Study 32333010 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (BCG+OPV vaccination at discharge)
Number of subjects: 268
Study 34051543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Augmented Reality (MAR) applications
Number of subjects: 122
Study 34051543 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods
Number of subjects: 122
Study 32213473 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging assessed PHQ-8
Number of subjects: 206
Study 32213473 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging assessed PHQ-2
Number of subjects: 206
Study 32213473 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging assessed GAD-2
Number of subjects: 206
Study 32213473 — intervention group
Group type: COMPARATOR
Intervention: INTW assessed SDS
Number of subjects: 206
Study 32213473 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging assessed PHQ-8 and GAD-2
Number of subjects: 206
Study 36105814 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose of ChAdOx1 nCoV-19 vaccine
Number of subjects: 16570
Study 36105814 — intervention group
Group type: COMPARATOR
Intervention: Full dose of ChAdOx1 nCoV-19 vaccine
Number of subjects: 16570
Study 34525977 — intervention group
Group type: EXPERIMENTAL
Intervention: VWM-B program
Number of subjects: 0
Study 34525977 — intervention group
Group type: COMPARATOR
Intervention: VWM-program (traditional verbal WM training)
Number of subjects: 0
Study 33616265 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mechanical lifting aids
Number of subjects: 569
Study 33616265 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of education
Number of subjects: 569
Study 33616265 — intervention group
Group type: COMPARATOR
Intervention: No intervention reported
Number of subjects: 569
Study 32297383 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrefined carbohydrate diet with the highest fiber content
Number of subjects: 0
Study 32297383 — intervention group
Group type: COMPARATOR
Intervention: Lower fiber diets (simple carbohydrate)
Number of subjects: 0
Study 32297383 — intervention group
Group type: COMPARATOR
Intervention: Lower fiber diets (unrefined carbohydrate)
Number of subjects: 0
Study 34210411 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) defined as at least 1 antiplatelet drug, statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and beta-blocker.
Number of subjects: 1472
Study 34210411 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) with ≤2 types of medications.
Number of subjects: 1472
Study 34210411 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) with 3 types of medications.
Number of subjects: 1472
Study 34210411 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with individual OMT agents (antiplatelet drug and statin).
Number of subjects: 1472
Study 32472686 — intervention group
Group type: EXPERIMENTAL
Intervention: Social accountability strategies using community scorecards
Number of subjects: 20
Study 35604539 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ofatumumab 20 mg administered via an autoinjector pen (test formulation)
Number of subjects: 0
Study 35604539 — intervention group
Group type: COMPARATOR
Intervention: Prefilled syringe (reference formulation)
Number of subjects: 0
Study 32311968 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBU cervical collar
Number of subjects: 60
Study 32311968 — intervention group
Group type: EXPERIMENTAL
Intervention: Philly cervical collar
Number of subjects: 60
Study 32311968 — intervention group
Group type: EXPERIMENTAL
Intervention: Necklite cervical collar
Number of subjects: 60
Study 33200296 — intervention group
Group type: EXPERIMENTAL
Intervention: ECL assay
Number of subjects: 2000
Study 33200296 — intervention group
Group type: COMPARATOR
Intervention: ELISA assay
Number of subjects: 2000
Study 33200296 — intervention group
Group type: EXPERIMENTAL
Intervention: Population PK model
Number of subjects: 2000
Study 34534317 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (100 µg/24 h)
Number of subjects: 32
Study 34534317 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (100 µg/24 h) + Insulin (160 IU)
Number of subjects: 32
Study 34534317 — intervention group
Group type: COMPARATOR
Intervention: Insulin (160 IU)
Number of subjects: 32
Study 34534317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32268795 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention (n=33 women, n=42 men)
Number of subjects: 150
Study 32268795 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention (n=33 women)
Number of subjects: 150
Study 32268795 — intervention group
Group type: COMPARATOR
Intervention: Untreated men (control group)
Number of subjects: 150
Study 32268795 — intervention group
Group type: COMPARATOR
Intervention: Untreated women (control group)
Number of subjects: 150
Study 32268795 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of rates of death and rehospitalization
Number of subjects: 150
Study 34233594 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian classical dance (n=18)
Number of subjects: 36
Study 34233594 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular training (n=18)
Number of subjects: 36
Study 34488241 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported basic knowledge of dyslexia
Number of subjects: 705
Study 34488241 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported awareness of local tools and processes for identifying dyslexia
Number of subjects: 705
Study 34488241 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported attitudes towards engaging in identifying dyslexia
Number of subjects: 705
Study 32588034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training (HSPT), 3 times weekly for 8 weeks
Number of subjects: 42
Study 34537827 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000+ IU/day vitamin D3
Number of subjects: 688
Study 34537827 — intervention group
Group type: COMPARATOR
Intervention: 200 IU/day vitamin D3 (comparison)
Number of subjects: 688
Study 33267641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusarium oxysporum f.sp. cubense (Foc) Race 1 isolates VCG 0125 and VCG 01220; characterized using PCR and morphological methods.
Number of subjects: 61
Study 33267641 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular confirmation of VCGs 0125 and 01220 using specific primer sets for Foc R1.
Number of subjects: 61
Study 33267641 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis using TEF1-α gene sequences.
Number of subjects: 61
Study 36360880 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week functionalistic stress recovery intervention
Number of subjects: 73
Study 36360880 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 73
Study 33203458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic mobilization intervention
Number of subjects: 20
Study 33203458 — intervention group
Group type: COMPARATOR
Intervention: Prescriptive mobilization intervention
Number of subjects: 20
Study 34505332 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messages about cardiac arrhythmias sent two times a week for 8 weeks
Number of subjects: 66
Study 34189934 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer approach
Number of subjects: 184
Study 34189934 — intervention group
Group type: COMPARATOR
Intervention: Expert training
Number of subjects: 184
Study 32321083 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (12 treatment sessions)
Number of subjects: 24
Study 32321083 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 24
Study 34491388 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-type prebiotics for 12 weeks
Number of subjects: 16
Study 34491388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32859142 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine (3 mg/kg)
Number of subjects: 15
Study 32859142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 15
Study 33198565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive demands (CD) during static stance tasks
Number of subjects: 34
Study 33198565 — intervention group
Group type: COMPARATOR
Intervention: Postural demands (PD) in three positions: feet apart, feet together, tandem feet
Number of subjects: 34
Study 35643561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-chop technique using a reverse chopper
Number of subjects: 44
Study 35643561 — intervention group
Group type: COMPARATOR
Intervention: Classic stop-and-chop technique
Number of subjects: 44
Study 33662928 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol mouth rinse (MEN MR)
Number of subjects: 9
Study 33662928 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (placebo MR)
Number of subjects: 9
Study 34196161 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based high-intensity aerobic interval training (HIAIT)/modified group-based HIAIT intervention (m-Ullevaal)
Number of subjects: 120
Study 34196161 — intervention group
Group type: COMPARATOR
Intervention: Moderate continuous training (MICT)
Number of subjects: 120
Study 34176716 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 69
Study 32747200 — intervention group
Group type: EXPERIMENTAL
Intervention: Retzius-sparing approach
Number of subjects: 0
Study 32747200 — intervention group
Group type: COMPARATOR
Intervention: Traditional anterior transperitoneal approach
Number of subjects: 0
Study 32747200 — intervention group
Group type: COMPARATOR
Intervention: Extraperitoneal approach
Number of subjects: 0
Study 32747200 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 0
Study 32747200 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical dissection techniques
Number of subjects: 0
Study 32747200 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial prostatectomies
Number of subjects: 0
Study 35710215 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) + Routine Physical Therapy (RPT)
Number of subjects: 90
Study 35710215 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Vertebral Mobilization (PVM) + Routine Physical Therapy (RPT)
Number of subjects: 90
Study 35710215 — intervention group
Group type: COMPARATOR
Intervention: Routine Physical Therapy (RPT)
Number of subjects: 90
Study 35710215 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between PVM + RPT and PNF + RPT
Number of subjects: 90
Study 33078480 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day crocin for 12 weeks
Number of subjects: 60
Study 33078480 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 36067791 — intervention group
Group type: EXPERIMENTAL
Intervention: Honglilai Vaginal Cream (0.625 mg/g) once daily for 3 weeks
Number of subjects: 435
Study 36067791 — intervention group
Group type: COMPARATOR
Intervention: Premarin Vaginal Cream (0.625 mg/g) once daily for 3 weeks
Number of subjects: 435
Study 34801009 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust‐Based Relational Intervention® (TBRI®)
Number of subjects: 360
Study 34383975 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine treatment
Number of subjects: 0
Study 34011197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 16
Study 33568163 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management model led by information nurses (observation group)
Number of subjects: 1562